Zandelisib Active Not Recruiting Phase 1 Trials for Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma Treatment

IndicationsStatusPurposePhase
Active Not RecruitingTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT03985189Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma